Cargando…

Botulinum toxin and benign prostatic hyperplasia

Benign prostatic hyperplasia (BPH) is a clinical condition where lower urinary tract symptoms are caused by both a physically obstructing prostate as well as tight smooth muscles around the bladder outlet. Treatment of this condition with botulinum toxin has been used since 2003, but this interest h...

Descripción completa

Detalles Bibliográficos
Autor principal: Ng, Lay Guat
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Second Military Medical University 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5780293/
https://www.ncbi.nlm.nih.gov/pubmed/29379734
http://dx.doi.org/10.1016/j.ajur.2017.11.003
_version_ 1783294706146344960
author Ng, Lay Guat
author_facet Ng, Lay Guat
author_sort Ng, Lay Guat
collection PubMed
description Benign prostatic hyperplasia (BPH) is a clinical condition where lower urinary tract symptoms are caused by both a physically obstructing prostate as well as tight smooth muscles around the bladder outlet. Treatment of this condition with botulinum toxin has been used since 2003, but this interest has somewhat died down after two large randomized controlled trials (RCTs) showing equivalence of results between their treatment and placebo arms. However, with review of animal studies and unexplained exaggerated effect of the placebo arms of the two RCTs, together with recent data of sustained benefits after 18 months of treatment, the place of botulinum toxin in the BPH field is probably still present.
format Online
Article
Text
id pubmed-5780293
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Second Military Medical University
record_format MEDLINE/PubMed
spelling pubmed-57802932018-01-29 Botulinum toxin and benign prostatic hyperplasia Ng, Lay Guat Asian J Urol Review Benign prostatic hyperplasia (BPH) is a clinical condition where lower urinary tract symptoms are caused by both a physically obstructing prostate as well as tight smooth muscles around the bladder outlet. Treatment of this condition with botulinum toxin has been used since 2003, but this interest has somewhat died down after two large randomized controlled trials (RCTs) showing equivalence of results between their treatment and placebo arms. However, with review of animal studies and unexplained exaggerated effect of the placebo arms of the two RCTs, together with recent data of sustained benefits after 18 months of treatment, the place of botulinum toxin in the BPH field is probably still present. Second Military Medical University 2018-01 2017-11-22 /pmc/articles/PMC5780293/ /pubmed/29379734 http://dx.doi.org/10.1016/j.ajur.2017.11.003 Text en © 2018 Editorial Office of Asian Journal of Urology. Production and hosting by Elsevier B.V. http://creativecommons.org/licenses/by-nc-nd/4.0/ This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
spellingShingle Review
Ng, Lay Guat
Botulinum toxin and benign prostatic hyperplasia
title Botulinum toxin and benign prostatic hyperplasia
title_full Botulinum toxin and benign prostatic hyperplasia
title_fullStr Botulinum toxin and benign prostatic hyperplasia
title_full_unstemmed Botulinum toxin and benign prostatic hyperplasia
title_short Botulinum toxin and benign prostatic hyperplasia
title_sort botulinum toxin and benign prostatic hyperplasia
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5780293/
https://www.ncbi.nlm.nih.gov/pubmed/29379734
http://dx.doi.org/10.1016/j.ajur.2017.11.003
work_keys_str_mv AT nglayguat botulinumtoxinandbenignprostatichyperplasia